score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8253	166.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat157	MEL-IPI_Pat157-Tumor-SM-7A15B	MEL-IPI_Pat157-Normal-SM-5VWIH
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat157	MEL-IPI_Pat157-Tumor-SM-7A15B	
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L2198I	0.024	208.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0				ATM p.L2198I (Missense)	1.0	MEL-IPI_Pat157	MEL-IPI_Pat157-Tumor-SM-7A15B	MEL-IPI_Pat157-Normal-SM-5VWIH
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.R1443Q	0.3904	228.0	8e-06	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA1 p.R1443Q (Missense)	1.0	MEL-IPI_Pat157	MEL-IPI_Pat157-Tumor-SM-7A15B	MEL-IPI_Pat157-Normal-SM-5VWIH
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.L716F	0.0172	348.0	0.0	0.0																Investigate Actionability	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				STAG2 p.L716F (Missense)		MEL-IPI_Pat157	MEL-IPI_Pat157-Tumor-SM-7A15B	MEL-IPI_Pat157-Normal-SM-5VWIH
Investigate Actionability			Clinical evidence	Copy Number	ESR1	Deletion				0.0	0.0																Investigate Actionability	0.0	Ampifications of ESR1 was significantly associated with poor disease-free survival and overall survival in a study of 99 patients with ER-positive breast cancer tumors.	Nielsen KV, Ejlertsen B, Muller S, et al. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2011;127(2):345-55.	https://doi.org/10.1007/s10549-010-0984-y	0				ESR1 Deletion		MEL-IPI_Pat157	MEL-IPI_Pat157-Tumor-SM-7A15B	
Biologically Relevant				Somatic Variant	NF1	Missense	p.Q1399K	0.0194	309.0	0.0	0.0																					0				NF1 p.Q1399K (Missense)		MEL-IPI_Pat157	MEL-IPI_Pat157-Tumor-SM-7A15B	MEL-IPI_Pat157-Normal-SM-5VWIH
Biologically Relevant				Copy Number	TMPRSS2	Amplification				0.0	0.0																					0				TMPRSS2 Amplification		MEL-IPI_Pat157	MEL-IPI_Pat157-Tumor-SM-7A15B	
Biologically Relevant				Copy Number	ROS1	Deletion				0.0	0.0																					0				ROS1 Deletion		MEL-IPI_Pat157	MEL-IPI_Pat157-Tumor-SM-7A15B	
Biologically Relevant				Copy Number	RAF1	Deletion				0.0	0.0																					0				RAF1 Deletion		MEL-IPI_Pat157	MEL-IPI_Pat157-Tumor-SM-7A15B	
Biologically Relevant				Copy Number	LIMK2	Deletion				0.0	0.0																					0				LIMK2 Deletion		MEL-IPI_Pat157	MEL-IPI_Pat157-Tumor-SM-7A15B	
Biologically Relevant				Copy Number	GATA3	Deletion				0.0	0.0																					0				GATA3 Deletion		MEL-IPI_Pat157	MEL-IPI_Pat157-Tumor-SM-7A15B	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.55_55A>AAAA (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.55_55A>AAAA (Insertion)		MEL-IPI_Pat157		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.354																									0				COSMIC Signature (version 2) 1 (35%)		MEL-IPI_Pat157		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.441																									0				COSMIC Signature (version 2) 7 (44%)		MEL-IPI_Pat157		
